In the last trading session, 2.4 million Adma Biologics Inc (NASDAQ:ADMA) shares changed hands as the company’s beta touched 0.45. With the company’s per share price at $20.19 changed hands at $0.5 or 2.54% during last session, the market valuation stood at $4.82B. ADMA’s last price was a discount, traded about -27.14% off its 52-week high of $25.67. The share price had its 52-week low at $8.91, which suggests the last value was 55.87% up since then.
Analysts gave the Adma Biologics Inc (ADMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended ADMA as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Adma Biologics Inc’s EPS for the current quarter is expected to be 0.14.
Adma Biologics Inc (NASDAQ:ADMA) trade information
Instantly ADMA was in green as seen at the end of in last trading. With action -1.27%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 17.73%, with the 5-day performance at -1.27% in the red. However, in the 30-day time frame, Adma Biologics Inc (NASDAQ:ADMA) is -5.26% down.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need a downside of -26.19% from its current market value. According to analyst projections, ADMA’s forecast low is 14 with 18 as the target high. To hit the forecast high, the stock’s price needs a 10.85% surge from its current level, while the stock would need to tank 30.66% for it to hit the projected low.
Adma Biologics Inc (ADMA) estimates and forecasts
Year-over-year growth is forecast to reach 19.90% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 124.13M. 3 analysts are of the opinion that Adma Biologics Inc’s revenue for the current quarter will be 133.4M. The company’s revenue for the corresponding quarters a year ago was 107.19M and 119.84M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 15.81%. The estimates for the next quarter sales put growth at 11.32%.
The 2025 estimates are for Adma Biologics Inc earnings to increase by 31.94%, but the outlook for the next 5-year period is at 39.25% per year.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.2459% or 14.52 million shares worth $162.3 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 14.62 shares estimated at $295.13 million under it, the former controlled 6.12% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.93% of the shares, roughly 7.0 shares worth around $141.37 million.
